nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—hematologic cancer	0.239	0.893	CbGaD
Sulindac—osteoarthritis—Prednisone—hematologic cancer	0.224	1	CpDpCtD
Sulindac—ALB—hematologic cancer	0.0286	0.107	CbGaD
Sulindac—PTGS2—Lenalidomide—hematologic cancer	0.0241	0.0909	CbGbCtD
Sulindac—CYP1A2—Anagrelide—hematologic cancer	0.0131	0.0495	CbGbCtD
Sulindac—CYP1A1—Methoxsalen—hematologic cancer	0.0131	0.0494	CbGbCtD
Sulindac—PTGS2—Thalidomide—hematologic cancer	0.0129	0.0485	CbGbCtD
Sulindac—PTGS1—Bortezomib—hematologic cancer	0.0125	0.047	CbGbCtD
Sulindac—CYP1A1—Bortezomib—hematologic cancer	0.0125	0.047	CbGbCtD
Sulindac—CYP1A1—Daunorubicin—hematologic cancer	0.012	0.045	CbGbCtD
Sulindac—PTGS1—Thalidomide—hematologic cancer	0.0109	0.041	CbGbCtD
Sulindac—CYP1A1—Thalidomide—hematologic cancer	0.0109	0.041	CbGbCtD
Sulindac—PTGS1—Ifosfamide—hematologic cancer	0.00958	0.0361	CbGbCtD
Sulindac—CYP1A1—Dacarbazine—hematologic cancer	0.00936	0.0352	CbGbCtD
Sulindac—PTGS1—Imatinib—hematologic cancer	0.00916	0.0345	CbGbCtD
Sulindac—PTGS2—Triamcinolone—hematologic cancer	0.00894	0.0336	CbGbCtD
Sulindac—PTGS2—Betamethasone—hematologic cancer	0.00767	0.0289	CbGbCtD
Sulindac—CYP1A1—Dasatinib—hematologic cancer	0.00735	0.0277	CbGbCtD
Sulindac—CYP1A2—Carmustine—hematologic cancer	0.0069	0.026	CbGbCtD
Sulindac—ALB—Imatinib—hematologic cancer	0.00684	0.0257	CbGbCtD
Sulindac—CYP1A2—Methoxsalen—hematologic cancer	0.00587	0.0221	CbGbCtD
Sulindac—CYP1A2—Bortezomib—hematologic cancer	0.00558	0.021	CbGbCtD
Sulindac—PTGS2—Cisplatin—hematologic cancer	0.00552	0.0208	CbGbCtD
Sulindac—PTGS2—Etoposide—hematologic cancer	0.00542	0.0204	CbGbCtD
Sulindac—CYP1A2—Daunorubicin—hematologic cancer	0.00534	0.0201	CbGbCtD
Sulindac—CYP1A2—Alitretinoin—hematologic cancer	0.00523	0.0197	CbGbCtD
Sulindac—CYP1A2—Thalidomide—hematologic cancer	0.00486	0.0183	CbGbCtD
Sulindac—PTGS1—Etoposide—hematologic cancer	0.00458	0.0172	CbGbCtD
Sulindac—ALB—Prednisone—hematologic cancer	0.0045	0.017	CbGbCtD
Sulindac—PTGS2—Dexamethasone—hematologic cancer	0.00446	0.0168	CbGbCtD
Sulindac—ALB—Irinotecan—hematologic cancer	0.00427	0.0161	CbGbCtD
Sulindac—CYP1A2—Dacarbazine—hematologic cancer	0.00418	0.0157	CbGbCtD
Sulindac—CYP1A2—Imatinib—hematologic cancer	0.00409	0.0154	CbGbCtD
Sulindac—CYP1A1—Dexamethasone—hematologic cancer	0.00377	0.0142	CbGbCtD
Sulindac—PTGDR2—hematopoietic system—hematologic cancer	0.00335	0.109	CbGeAlD
Sulindac—CYP1A2—Dasatinib—hematologic cancer	0.00329	0.0124	CbGbCtD
Sulindac—PTGS2—ovarian follicle—hematologic cancer	0.00278	0.0903	CbGeAlD
Sulindac—SLC22A6—Methotrexate—hematologic cancer	0.00265	0.00999	CbGbCtD
Sulindac—ALB—Methotrexate—hematologic cancer	0.00226	0.00851	CbGbCtD
Sulindac—PTGDR2—blood—hematologic cancer	0.00222	0.0722	CbGeAlD
Sulindac—CYP1A2—Etoposide—hematologic cancer	0.00205	0.0077	CbGbCtD
Sulindac—AKR1B1—hematopoietic system—hematologic cancer	0.00178	0.0579	CbGeAlD
Sulindac—PPARD—hematopoietic system—hematologic cancer	0.0014	0.0455	CbGeAlD
Sulindac—AKR1B1—gonad—hematologic cancer	0.00136	0.044	CbGeAlD
Sulindac—MAPK3—hematopoietic system—hematologic cancer	0.00129	0.042	CbGeAlD
Sulindac—AKR1B1—blood—hematologic cancer	0.00118	0.0384	CbGeAlD
Sulindac—AKR1B1—bone marrow—hematologic cancer	0.00114	0.0371	CbGeAlD
Sulindac—AKR1B1—lung—hematologic cancer	0.00104	0.0336	CbGeAlD
Sulindac—MAPK3—gonad—hematologic cancer	0.000983	0.0319	CbGeAlD
Sulindac—AKR1B1—testis—hematologic cancer	0.000977	0.0317	CbGeAlD
Sulindac—MAPK3—blood—hematologic cancer	0.000856	0.0278	CbGeAlD
Sulindac—MAPK3—bone marrow—hematologic cancer	0.000828	0.0269	CbGeAlD
Sulindac—PPARD—lung—hematologic cancer	0.000814	0.0265	CbGeAlD
Sulindac—PPARD—testis—hematologic cancer	0.000768	0.025	CbGeAlD
Sulindac—MAPK3—lung—hematologic cancer	0.000751	0.0244	CbGeAlD
Sulindac—MAPK3—testis—hematologic cancer	0.000708	0.023	CbGeAlD
Sulindac—AKR1B1—lymph node—hematologic cancer	0.000708	0.023	CbGeAlD
Sulindac—PPARD—lymph node—hematologic cancer	0.000557	0.0181	CbGeAlD
Sulindac—MAPK3—lymph node—hematologic cancer	0.000513	0.0167	CbGeAlD
Sulindac—CYP1A2—hematopoietic system—hematologic cancer	0.000405	0.0132	CbGeAlD
Sulindac—CYP1A1—hematopoietic system—hematologic cancer	0.0004	0.013	CbGeAlD
Sulindac—PTGS1—hematopoietic system—hematologic cancer	0.000351	0.0114	CbGeAlD
Sulindac—ALB—testis—hematologic cancer	0.000338	0.011	CbGeAlD
Sulindac—PTGS2—hematopoietic system—hematologic cancer	0.000336	0.0109	CbGeAlD
Sulindac—CYP1A2—blood—hematologic cancer	0.000269	0.00872	CbGeAlD
Sulindac—CYP1A1—blood—hematologic cancer	0.000265	0.0086	CbGeAlD
Sulindac—ALB—lymph node—hematologic cancer	0.000245	0.00795	CbGeAlD
Sulindac—CYP1A2—lung—hematologic cancer	0.000235	0.00765	CbGeAlD
Sulindac—PTGS1—blood—hematologic cancer	0.000233	0.00756	CbGeAlD
Sulindac—CYP1A1—lung—hematologic cancer	0.000232	0.00754	CbGeAlD
Sulindac—PTGS2—blood—hematologic cancer	0.000222	0.00723	CbGeAlD
Sulindac—PTGS2—bone marrow—hematologic cancer	0.000215	0.00699	CbGeAlD
Sulindac—PTGS1—lung—hematologic cancer	0.000204	0.00663	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.000196	0.21	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.000196	0.21	CbGdCrCtD
Sulindac—PTGS2—lung—hematologic cancer	0.000195	0.00633	CbGeAlD
Sulindac—PTGS1—testis—hematologic cancer	0.000192	0.00625	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.000192	0.205	CbGdCrCtD
Sulindac—CYP1A1—lymph node—hematologic cancer	0.000159	0.00516	CbGeAlD
Sulindac—PTGS1—lymph node—hematologic cancer	0.00014	0.00453	CbGeAlD
Sulindac—PTGS2—lymph node—hematologic cancer	0.000133	0.00433	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	0.000118	0.126	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	0.000118	0.126	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	0.000116	0.124	CbGdCrCtD
Sulindac—Discomfort—Prednisone—hematologic cancer	1.38e-05	0.000119	CcSEcCtD
Sulindac—Rash—Gemcitabine—hematologic cancer	1.38e-05	0.000119	CcSEcCtD
Sulindac—Dermatitis—Gemcitabine—hematologic cancer	1.38e-05	0.000119	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—hematologic cancer	1.38e-05	0.000119	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—hematologic cancer	1.37e-05	0.000119	CcSEcCtD
Sulindac—Headache—Gemcitabine—hematologic cancer	1.37e-05	0.000119	CcSEcCtD
Sulindac—Nausea—Vincristine—hematologic cancer	1.37e-05	0.000119	CcSEcCtD
Sulindac—Flushing—Epirubicin—hematologic cancer	1.37e-05	0.000118	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—hematologic cancer	1.36e-05	0.000118	CcSEcCtD
Sulindac—Hypersensitivity—Prednisolone—hematologic cancer	1.36e-05	0.000118	CcSEcCtD
Sulindac—Dyspepsia—Dexamethasone—hematologic cancer	1.35e-05	0.000117	CcSEcCtD
Sulindac—Dyspepsia—Betamethasone—hematologic cancer	1.35e-05	0.000117	CcSEcCtD
Sulindac—Urticaria—Triamcinolone—hematologic cancer	1.35e-05	0.000117	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Asthenia—Etoposide—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Body temperature increased—Triamcinolone—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Oedema—Prednisone—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Decreased appetite—Dexamethasone—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Decreased appetite—Betamethasone—hematologic cancer	1.34e-05	0.000116	CcSEcCtD
Sulindac—Nausea—Irinotecan—hematologic cancer	1.33e-05	0.000115	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—hematologic cancer	1.33e-05	0.000115	CcSEcCtD
Sulindac—Fatigue—Betamethasone—hematologic cancer	1.33e-05	0.000115	CcSEcCtD
Sulindac—Fatigue—Dexamethasone—hematologic cancer	1.33e-05	0.000115	CcSEcCtD
Sulindac—Chills—Epirubicin—hematologic cancer	1.32e-05	0.000115	CcSEcCtD
Sulindac—Pruritus—Etoposide—hematologic cancer	1.32e-05	0.000114	CcSEcCtD
Sulindac—Shock—Prednisone—hematologic cancer	1.32e-05	0.000114	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—hematologic cancer	1.32e-05	0.000114	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—hematologic cancer	1.31e-05	0.000114	CcSEcCtD
Sulindac—Tachycardia—Prednisone—hematologic cancer	1.31e-05	0.000113	CcSEcCtD
Sulindac—Alopecia—Epirubicin—hematologic cancer	1.3e-05	0.000113	CcSEcCtD
Sulindac—Nausea—Gemcitabine—hematologic cancer	1.3e-05	0.000113	CcSEcCtD
Sulindac—Vomiting—Cisplatin—hematologic cancer	1.3e-05	0.000112	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—hematologic cancer	1.29e-05	0.000112	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—hematologic cancer	1.29e-05	0.000112	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—hematologic cancer	1.29e-05	0.000112	CcSEcCtD
Sulindac—Rash—Cisplatin—hematologic cancer	1.29e-05	0.000111	CcSEcCtD
Sulindac—Dermatitis—Cisplatin—hematologic cancer	1.28e-05	0.000111	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—hematologic cancer	1.28e-05	0.000111	CcSEcCtD
Sulindac—Anorexia—Prednisone—hematologic cancer	1.28e-05	0.00011	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Anaemia—Methotrexate—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Feeling abnormal—Betamethasone—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Feeling abnormal—Dexamethasone—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Flushing—Doxorubicin—hematologic cancer	1.27e-05	0.00011	CcSEcCtD
Sulindac—Flatulence—Epirubicin—hematologic cancer	1.26e-05	0.000109	CcSEcCtD
Sulindac—Tension—Epirubicin—hematologic cancer	1.26e-05	0.000109	CcSEcCtD
Sulindac—Gastrointestinal pain—Betamethasone—hematologic cancer	1.26e-05	0.000109	CcSEcCtD
Sulindac—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.26e-05	0.000109	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—hematologic cancer	1.26e-05	0.000109	CcSEcCtD
Sulindac—Hypersensitivity—Triamcinolone—hematologic cancer	1.25e-05	0.000108	CcSEcCtD
Sulindac—Nervousness—Epirubicin—hematologic cancer	1.25e-05	0.000108	CcSEcCtD
Sulindac—Malaise—Methotrexate—hematologic cancer	1.24e-05	0.000107	CcSEcCtD
Sulindac—Dizziness—Etoposide—hematologic cancer	1.24e-05	0.000107	CcSEcCtD
Sulindac—Vertigo—Methotrexate—hematologic cancer	1.23e-05	0.000107	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—hematologic cancer	1.23e-05	0.000106	CcSEcCtD
Sulindac—Chills—Doxorubicin—hematologic cancer	1.22e-05	0.000106	CcSEcCtD
Sulindac—Urticaria—Dexamethasone—hematologic cancer	1.22e-05	0.000106	CcSEcCtD
Sulindac—Urticaria—Betamethasone—hematologic cancer	1.22e-05	0.000106	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.22e-05	0.000106	CcSEcCtD
Sulindac—Dizziness—Prednisolone—hematologic cancer	1.22e-05	0.000105	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—hematologic cancer	1.22e-05	0.000105	CcSEcCtD
Sulindac—Asthenia—Triamcinolone—hematologic cancer	1.22e-05	0.000105	CcSEcCtD
Sulindac—Body temperature increased—Dexamethasone—hematologic cancer	1.22e-05	0.000105	CcSEcCtD
Sulindac—Body temperature increased—Betamethasone—hematologic cancer	1.22e-05	0.000105	CcSEcCtD
Sulindac—Nausea—Cisplatin—hematologic cancer	1.21e-05	0.000105	CcSEcCtD
Sulindac—Insomnia—Prednisone—hematologic cancer	1.21e-05	0.000105	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—hematologic cancer	1.21e-05	0.000105	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—hematologic cancer	1.21e-05	0.000104	CcSEcCtD
Sulindac—Paraesthesia—Prednisone—hematologic cancer	1.2e-05	0.000104	CcSEcCtD
Sulindac—Pruritus—Triamcinolone—hematologic cancer	1.2e-05	0.000104	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—hematologic cancer	1.19e-05	0.000103	CcSEcCtD
Sulindac—Convulsion—Methotrexate—hematologic cancer	1.19e-05	0.000103	CcSEcCtD
Sulindac—Vomiting—Etoposide—hematologic cancer	1.19e-05	0.000103	CcSEcCtD
Sulindac—Anaemia—Epirubicin—hematologic cancer	1.19e-05	0.000103	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—hematologic cancer	1.18e-05	0.000102	CcSEcCtD
Sulindac—Rash—Etoposide—hematologic cancer	1.18e-05	0.000102	CcSEcCtD
Sulindac—Dermatitis—Etoposide—hematologic cancer	1.18e-05	0.000102	CcSEcCtD
Sulindac—Headache—Etoposide—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Myalgia—Methotrexate—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Chest pain—Methotrexate—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Tension—Doxorubicin—hematologic cancer	1.17e-05	0.000101	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—hematologic cancer	1.16e-05	0.000101	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—hematologic cancer	1.16e-05	0.000101	CcSEcCtD
Sulindac—Rash—Prednisolone—hematologic cancer	1.16e-05	0.000101	CcSEcCtD
Sulindac—Dermatitis—Prednisolone—hematologic cancer	1.16e-05	0.0001	CcSEcCtD
Sulindac—Malaise—Epirubicin—hematologic cancer	1.16e-05	0.0001	CcSEcCtD
Sulindac—Fatigue—Prednisone—hematologic cancer	1.15e-05	9.99e-05	CcSEcCtD
Sulindac—Headache—Prednisolone—hematologic cancer	1.15e-05	9.99e-05	CcSEcCtD
Sulindac—Discomfort—Methotrexate—hematologic cancer	1.15e-05	9.98e-05	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—hematologic cancer	1.15e-05	9.98e-05	CcSEcCtD
Sulindac—Vertigo—Epirubicin—hematologic cancer	1.15e-05	9.98e-05	CcSEcCtD
Sulindac—Syncope—Epirubicin—hematologic cancer	1.15e-05	9.96e-05	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—hematologic cancer	1.15e-05	9.94e-05	CcSEcCtD
Sulindac—Constipation—Prednisone—hematologic cancer	1.15e-05	9.91e-05	CcSEcCtD
Sulindac—Palpitations—Epirubicin—hematologic cancer	1.13e-05	9.82e-05	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—hematologic cancer	1.13e-05	9.76e-05	CcSEcCtD
Sulindac—Dizziness—Triamcinolone—hematologic cancer	1.12e-05	9.7e-05	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—hematologic cancer	1.12e-05	9.69e-05	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—hematologic cancer	1.12e-05	9.69e-05	CcSEcCtD
Sulindac—Convulsion—Epirubicin—hematologic cancer	1.11e-05	9.62e-05	CcSEcCtD
Sulindac—Nausea—Etoposide—hematologic cancer	1.11e-05	9.61e-05	CcSEcCtD
Sulindac—Hypertension—Epirubicin—hematologic cancer	1.11e-05	9.59e-05	CcSEcCtD
Sulindac—Feeling abnormal—Prednisone—hematologic cancer	1.1e-05	9.55e-05	CcSEcCtD
Sulindac—Asthenia—Dexamethasone—hematologic cancer	1.1e-05	9.55e-05	CcSEcCtD
Sulindac—Asthenia—Betamethasone—hematologic cancer	1.1e-05	9.55e-05	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—hematologic cancer	1.1e-05	9.54e-05	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—hematologic cancer	1.1e-05	9.5e-05	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—hematologic cancer	1.1e-05	9.49e-05	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—hematologic cancer	1.1e-05	9.48e-05	CcSEcCtD
Sulindac—Nausea—Prednisolone—hematologic cancer	1.09e-05	9.48e-05	CcSEcCtD
Sulindac—Chest pain—Epirubicin—hematologic cancer	1.09e-05	9.46e-05	CcSEcCtD
Sulindac—Myalgia—Epirubicin—hematologic cancer	1.09e-05	9.46e-05	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—hematologic cancer	1.09e-05	9.46e-05	CcSEcCtD
Sulindac—Pruritus—Dexamethasone—hematologic cancer	1.09e-05	9.42e-05	CcSEcCtD
Sulindac—Pruritus—Betamethasone—hematologic cancer	1.09e-05	9.42e-05	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—hematologic cancer	1.08e-05	9.37e-05	CcSEcCtD
Sulindac—Discomfort—Epirubicin—hematologic cancer	1.08e-05	9.34e-05	CcSEcCtD
Sulindac—Vomiting—Triamcinolone—hematologic cancer	1.08e-05	9.33e-05	CcSEcCtD
Sulindac—Malaise—Doxorubicin—hematologic cancer	1.07e-05	9.27e-05	CcSEcCtD
Sulindac—Rash—Triamcinolone—hematologic cancer	1.07e-05	9.25e-05	CcSEcCtD
Sulindac—Dermatitis—Triamcinolone—hematologic cancer	1.07e-05	9.24e-05	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—hematologic cancer	1.07e-05	9.23e-05	CcSEcCtD
Sulindac—Anorexia—Methotrexate—hematologic cancer	1.07e-05	9.23e-05	CcSEcCtD
Sulindac—Syncope—Doxorubicin—hematologic cancer	1.06e-05	9.22e-05	CcSEcCtD
Sulindac—Urticaria—Prednisone—hematologic cancer	1.06e-05	9.21e-05	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—hematologic cancer	1.06e-05	9.2e-05	CcSEcCtD
Sulindac—Headache—Triamcinolone—hematologic cancer	1.06e-05	9.19e-05	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—hematologic cancer	1.06e-05	9.16e-05	CcSEcCtD
Sulindac—Diarrhoea—Betamethasone—hematologic cancer	1.05e-05	9.11e-05	CcSEcCtD
Sulindac—Diarrhoea—Dexamethasone—hematologic cancer	1.05e-05	9.11e-05	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—hematologic cancer	1.05e-05	9.08e-05	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—hematologic cancer	1.05e-05	9.07e-05	CcSEcCtD
Sulindac—Oedema—Epirubicin—hematologic cancer	1.05e-05	9.07e-05	CcSEcCtD
Sulindac—Hypotension—Methotrexate—hematologic cancer	1.05e-05	9.05e-05	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—hematologic cancer	1.04e-05	9.03e-05	CcSEcCtD
Sulindac—Shock—Epirubicin—hematologic cancer	1.03e-05	8.92e-05	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—hematologic cancer	1.03e-05	8.91e-05	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—hematologic cancer	1.03e-05	8.88e-05	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—hematologic cancer	1.03e-05	8.87e-05	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—hematologic cancer	1.02e-05	8.85e-05	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.02e-05	8.83e-05	CcSEcCtD
Sulindac—Dizziness—Betamethasone—hematologic cancer	1.02e-05	8.8e-05	CcSEcCtD
Sulindac—Dizziness—Dexamethasone—hematologic cancer	1.02e-05	8.8e-05	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—hematologic cancer	1.01e-05	8.76e-05	CcSEcCtD
Sulindac—Insomnia—Methotrexate—hematologic cancer	1.01e-05	8.76e-05	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—hematologic cancer	1.01e-05	8.75e-05	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—hematologic cancer	1.01e-05	8.75e-05	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—hematologic cancer	1.01e-05	8.75e-05	CcSEcCtD
Sulindac—Nausea—Triamcinolone—hematologic cancer	1.01e-05	8.71e-05	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—hematologic cancer	1e-05	8.7e-05	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—hematologic cancer	9.99e-06	8.65e-05	CcSEcCtD
Sulindac—Anorexia—Epirubicin—hematologic cancer	9.98e-06	8.64e-05	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—hematologic cancer	9.98e-06	8.64e-05	CcSEcCtD
Sulindac—Somnolence—Methotrexate—hematologic cancer	9.95e-06	8.61e-05	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—hematologic cancer	9.87e-06	8.54e-05	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—hematologic cancer	9.85e-06	8.53e-05	CcSEcCtD
Sulindac—Hypotension—Epirubicin—hematologic cancer	9.79e-06	8.47e-05	CcSEcCtD
Sulindac—Vomiting—Dexamethasone—hematologic cancer	9.78e-06	8.46e-05	CcSEcCtD
Sulindac—Vomiting—Betamethasone—hematologic cancer	9.78e-06	8.46e-05	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—hematologic cancer	9.73e-06	8.42e-05	CcSEcCtD
Sulindac—Rash—Betamethasone—hematologic cancer	9.7e-06	8.39e-05	CcSEcCtD
Sulindac—Rash—Dexamethasone—hematologic cancer	9.7e-06	8.39e-05	CcSEcCtD
Sulindac—Oedema—Doxorubicin—hematologic cancer	9.69e-06	8.39e-05	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—hematologic cancer	9.69e-06	8.39e-05	CcSEcCtD
Sulindac—Dermatitis—Dexamethasone—hematologic cancer	9.69e-06	8.39e-05	CcSEcCtD
Sulindac—Dermatitis—Betamethasone—hematologic cancer	9.69e-06	8.39e-05	CcSEcCtD
Sulindac—Fatigue—Methotrexate—hematologic cancer	9.65e-06	8.35e-05	CcSEcCtD
Sulindac—Headache—Betamethasone—hematologic cancer	9.63e-06	8.34e-05	CcSEcCtD
Sulindac—Headache—Dexamethasone—hematologic cancer	9.63e-06	8.34e-05	CcSEcCtD
Sulindac—Asthenia—Prednisone—hematologic cancer	9.61e-06	8.32e-05	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.54e-06	8.26e-05	CcSEcCtD
Sulindac—Shock—Doxorubicin—hematologic cancer	9.53e-06	8.25e-05	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—hematologic cancer	9.49e-06	8.21e-05	CcSEcCtD
Sulindac—Pruritus—Prednisone—hematologic cancer	9.47e-06	8.2e-05	CcSEcCtD
Sulindac—Insomnia—Epirubicin—hematologic cancer	9.47e-06	8.2e-05	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—hematologic cancer	9.46e-06	8.19e-05	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—hematologic cancer	9.41e-06	8.14e-05	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—hematologic cancer	9.37e-06	8.11e-05	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—hematologic cancer	9.34e-06	8.08e-05	CcSEcCtD
Sulindac—Somnolence—Epirubicin—hematologic cancer	9.31e-06	8.06e-05	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—hematologic cancer	9.24e-06	8e-05	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—hematologic cancer	9.22e-06	7.98e-05	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—hematologic cancer	9.22e-06	7.98e-05	CcSEcCtD
Sulindac—Diarrhoea—Prednisone—hematologic cancer	9.16e-06	7.93e-05	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—hematologic cancer	9.15e-06	7.92e-05	CcSEcCtD
Sulindac—Nausea—Dexamethasone—hematologic cancer	9.13e-06	7.91e-05	CcSEcCtD
Sulindac—Nausea—Betamethasone—hematologic cancer	9.13e-06	7.91e-05	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—hematologic cancer	9.1e-06	7.88e-05	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—hematologic cancer	9.06e-06	7.84e-05	CcSEcCtD
Sulindac—Fatigue—Epirubicin—hematologic cancer	9.03e-06	7.82e-05	CcSEcCtD
Sulindac—Constipation—Epirubicin—hematologic cancer	8.96e-06	7.75e-05	CcSEcCtD
Sulindac—Urticaria—Methotrexate—hematologic cancer	8.89e-06	7.7e-05	CcSEcCtD
Sulindac—Dizziness—Prednisone—hematologic cancer	8.86e-06	7.67e-05	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—hematologic cancer	8.85e-06	7.66e-05	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.83e-06	7.64e-05	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—hematologic cancer	8.77e-06	7.59e-05	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—hematologic cancer	8.7e-06	7.53e-05	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—hematologic cancer	8.64e-06	7.48e-05	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—hematologic cancer	8.63e-06	7.47e-05	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—hematologic cancer	8.62e-06	7.46e-05	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—hematologic cancer	8.56e-06	7.41e-05	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—hematologic cancer	8.53e-06	7.38e-05	CcSEcCtD
Sulindac—Vomiting—Prednisone—hematologic cancer	8.51e-06	7.37e-05	CcSEcCtD
Sulindac—Rash—Prednisone—hematologic cancer	8.44e-06	7.31e-05	CcSEcCtD
Sulindac—Dermatitis—Prednisone—hematologic cancer	8.44e-06	7.3e-05	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—hematologic cancer	8.42e-06	7.29e-05	CcSEcCtD
Sulindac—Headache—Prednisone—hematologic cancer	8.39e-06	7.26e-05	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—hematologic cancer	8.36e-06	7.23e-05	CcSEcCtD
Sulindac—Urticaria—Epirubicin—hematologic cancer	8.32e-06	7.2e-05	CcSEcCtD
Sulindac—Constipation—Doxorubicin—hematologic cancer	8.29e-06	7.17e-05	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—hematologic cancer	8.28e-06	7.17e-05	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—hematologic cancer	8.25e-06	7.14e-05	CcSEcCtD
Sulindac—Asthenia—Methotrexate—hematologic cancer	8.03e-06	6.95e-05	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—hematologic cancer	7.99e-06	6.91e-05	CcSEcCtD
Sulindac—Nausea—Prednisone—hematologic cancer	7.95e-06	6.89e-05	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.92e-06	6.86e-05	CcSEcCtD
Sulindac—Pruritus—Methotrexate—hematologic cancer	7.92e-06	6.85e-05	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—hematologic cancer	7.72e-06	6.68e-05	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—hematologic cancer	7.7e-06	6.66e-05	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—hematologic cancer	7.66e-06	6.63e-05	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—hematologic cancer	7.66e-06	6.63e-05	CcSEcCtD
Sulindac—Asthenia—Epirubicin—hematologic cancer	7.51e-06	6.5e-05	CcSEcCtD
Sulindac—Pruritus—Epirubicin—hematologic cancer	7.41e-06	6.41e-05	CcSEcCtD
Sulindac—Dizziness—Methotrexate—hematologic cancer	7.4e-06	6.41e-05	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—hematologic cancer	7.17e-06	6.2e-05	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—hematologic cancer	7.14e-06	6.18e-05	CcSEcCtD
Sulindac—Vomiting—Methotrexate—hematologic cancer	7.12e-06	6.16e-05	CcSEcCtD
Sulindac—Rash—Methotrexate—hematologic cancer	7.06e-06	6.11e-05	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—hematologic cancer	7.05e-06	6.1e-05	CcSEcCtD
Sulindac—Headache—Methotrexate—hematologic cancer	7.01e-06	6.07e-05	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—hematologic cancer	6.95e-06	6.02e-05	CcSEcCtD
Sulindac—Dizziness—Epirubicin—hematologic cancer	6.93e-06	6e-05	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—hematologic cancer	6.86e-06	5.94e-05	CcSEcCtD
Sulindac—Vomiting—Epirubicin—hematologic cancer	6.66e-06	5.76e-05	CcSEcCtD
Sulindac—Nausea—Methotrexate—hematologic cancer	6.65e-06	5.75e-05	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—hematologic cancer	6.63e-06	5.74e-05	CcSEcCtD
Sulindac—Rash—Epirubicin—hematologic cancer	6.6e-06	5.72e-05	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—hematologic cancer	6.6e-06	5.71e-05	CcSEcCtD
Sulindac—Headache—Epirubicin—hematologic cancer	6.56e-06	5.68e-05	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—hematologic cancer	6.41e-06	5.55e-05	CcSEcCtD
Sulindac—Nausea—Epirubicin—hematologic cancer	6.22e-06	5.39e-05	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—hematologic cancer	6.16e-06	5.33e-05	CcSEcCtD
Sulindac—Rash—Doxorubicin—hematologic cancer	6.11e-06	5.29e-05	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—hematologic cancer	6.1e-06	5.28e-05	CcSEcCtD
Sulindac—Headache—Doxorubicin—hematologic cancer	6.07e-06	5.26e-05	CcSEcCtD
Sulindac—Nausea—Doxorubicin—hematologic cancer	5.76e-06	4.98e-05	CcSEcCtD
Sulindac—ALB—Hemostasis—PIK3CB—hematologic cancer	1.29e-06	1.35e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.29e-06	1.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK14—hematologic cancer	1.28e-06	1.34e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SPHK1—hematologic cancer	1.28e-06	1.33e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.27e-06	1.33e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—hematologic cancer	1.27e-06	1.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—hematologic cancer	1.26e-06	1.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—hematologic cancer	1.26e-06	1.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.26e-06	1.31e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	1.25e-06	1.31e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYCS—hematologic cancer	1.25e-06	1.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FN1—hematologic cancer	1.24e-06	1.3e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HSP90AA1—hematologic cancer	1.24e-06	1.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—hematologic cancer	1.24e-06	1.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BAD—hematologic cancer	1.23e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NFKBIA—hematologic cancer	1.23e-06	1.28e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—UGT1A1—hematologic cancer	1.23e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1B—hematologic cancer	1.22e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1A—hematologic cancer	1.22e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—hematologic cancer	1.22e-06	1.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOTCH1—hematologic cancer	1.21e-06	1.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—hematologic cancer	1.2e-06	1.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NQO1—hematologic cancer	1.2e-06	1.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CD44—hematologic cancer	1.2e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—hematologic cancer	1.2e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.2e-06	1.25e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—hematologic cancer	1.2e-06	1.25e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—hematologic cancer	1.2e-06	1.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC22A1—hematologic cancer	1.19e-06	1.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CRABP1—hematologic cancer	1.19e-06	1.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK8—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CD80—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CG—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—hematologic cancer	1.19e-06	1.24e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.18e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—hematologic cancer	1.17e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFB—hematologic cancer	1.17e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTPN11—hematologic cancer	1.17e-06	1.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALOX5—hematologic cancer	1.16e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EP300—hematologic cancer	1.16e-06	1.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TSC2—hematologic cancer	1.14e-06	1.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—hematologic cancer	1.14e-06	1.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NCOR1—hematologic cancer	1.14e-06	1.19e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYCS—hematologic cancer	1.14e-06	1.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CREB1—hematologic cancer	1.13e-06	1.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSP90AA1—hematologic cancer	1.13e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—hematologic cancer	1.13e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1A—hematologic cancer	1.13e-06	1.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NUP98—hematologic cancer	1.12e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—hematologic cancer	1.12e-06	1.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—hematologic cancer	1.12e-06	1.17e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.12e-06	1.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.11e-06	1.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—hematologic cancer	1.11e-06	1.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6R—hematologic cancer	1.1e-06	1.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CREBBP—hematologic cancer	1.1e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—hematologic cancer	1.1e-06	1.15e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR3—hematologic cancer	1.1e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADCY7—hematologic cancer	1.09e-06	1.14e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA3—hematologic cancer	1.09e-06	1.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—hematologic cancer	1.09e-06	1.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—hematologic cancer	1.08e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NUP214—hematologic cancer	1.08e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.07e-06	1.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EP300—hematologic cancer	1.07e-06	1.12e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EP300—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTR—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—hematologic cancer	1.06e-06	1.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAP2K1—hematologic cancer	1.05e-06	1.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—hematologic cancer	1.04e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—hematologic cancer	1.04e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BAD—hematologic cancer	1.04e-06	1.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—hematologic cancer	1.04e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—hematologic cancer	1.04e-06	1.09e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—hematologic cancer	1.03e-06	1.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOTCH1—hematologic cancer	1.03e-06	1.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—hematologic cancer	1.02e-06	1.07e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.02e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.01e-06	1.06e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD80—hematologic cancer	1.01e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NCOR1—hematologic cancer	1.01e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—hematologic cancer	1.01e-06	1.06e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—hematologic cancer	1.01e-06	1.05e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—hematologic cancer	1.01e-06	1.05e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—hematologic cancer	1.01e-06	1.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—hematologic cancer	1e-06	1.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—hematologic cancer	1e-06	1.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—hematologic cancer	1e-06	1.05e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—hematologic cancer	1e-06	1.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGF2—hematologic cancer	9.99e-07	1.05e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—hematologic cancer	9.95e-07	1.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.95e-07	1.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTPN11—hematologic cancer	9.91e-07	1.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SDC1—hematologic cancer	9.87e-07	1.03e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CREBBP—hematologic cancer	9.86e-07	1.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3R1—hematologic cancer	9.86e-07	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	9.69e-07	1.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CREB1—hematologic cancer	9.6e-07	1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JAK2—hematologic cancer	9.58e-07	1e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—hematologic cancer	9.53e-07	9.97e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—hematologic cancer	9.48e-07	9.92e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—hematologic cancer	9.48e-07	9.92e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.43e-07	9.87e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—hematologic cancer	9.39e-07	9.82e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6R—hematologic cancer	9.36e-07	9.8e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—hematologic cancer	9.35e-07	9.78e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—hematologic cancer	9.35e-07	9.78e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CREBBP—hematologic cancer	9.35e-07	9.78e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—hematologic cancer	9.34e-07	9.77e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—hematologic cancer	9.33e-07	9.76e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	9.31e-07	9.74e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—hematologic cancer	9.31e-07	9.74e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—hematologic cancer	9.25e-07	9.68e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—hematologic cancer	9.23e-07	9.66e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—hematologic cancer	9.2e-07	9.63e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOR1—hematologic cancer	9.2e-07	9.63e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—hematologic cancer	9.1e-07	9.52e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—hematologic cancer	9.1e-07	9.52e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAP2K1—hematologic cancer	8.92e-07	9.34e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—hematologic cancer	8.92e-07	9.33e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.91e-07	9.32e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—hematologic cancer	8.86e-07	9.27e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.86e-07	9.27e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3R1—hematologic cancer	8.83e-07	9.24e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—hematologic cancer	8.69e-07	9.09e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—hematologic cancer	8.62e-07	9.02e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—hematologic cancer	8.58e-07	8.97e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—hematologic cancer	8.57e-07	8.96e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—hematologic cancer	8.54e-07	8.93e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGF2—hematologic cancer	8.49e-07	8.88e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—hematologic cancer	8.44e-07	8.83e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CD44—hematologic cancer	8.4e-07	8.78e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NQO1—hematologic cancer	8.4e-07	8.78e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3R1—hematologic cancer	8.37e-07	8.76e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—hematologic cancer	8.37e-07	8.75e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—hematologic cancer	8.35e-07	8.74e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—hematologic cancer	8.31e-07	8.7e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.22e-07	8.6e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—hematologic cancer	8.15e-07	8.53e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—hematologic cancer	8.14e-07	8.52e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—JAK2—hematologic cancer	8.13e-07	8.51e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—hematologic cancer	8.13e-07	8.51e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—hematologic cancer	8.13e-07	8.5e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYCS—hematologic cancer	7.94e-07	8.31e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—hematologic cancer	7.94e-07	8.31e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—hematologic cancer	7.94e-07	8.3e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—hematologic cancer	7.92e-07	8.29e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	7.89e-07	8.26e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1A—hematologic cancer	7.88e-07	8.24e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—hematologic cancer	7.87e-07	8.23e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—hematologic cancer	7.86e-07	8.23e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.86e-07	8.22e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CREBBP—hematologic cancer	7.83e-07	8.19e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—hematologic cancer	7.73e-07	8.08e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—hematologic cancer	7.73e-07	8.08e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—hematologic cancer	7.71e-07	8.07e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK8—hematologic cancer	7.69e-07	8.05e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—hematologic cancer	7.67e-07	8.02e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—hematologic cancer	7.61e-07	7.97e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—hematologic cancer	7.6e-07	7.95e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EP300—hematologic cancer	7.5e-07	7.84e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—hematologic cancer	7.49e-07	7.84e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—hematologic cancer	7.42e-07	7.77e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—hematologic cancer	7.33e-07	7.67e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—hematologic cancer	7.33e-07	7.67e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—hematologic cancer	7.29e-07	7.63e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—hematologic cancer	7.28e-07	7.62e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—hematologic cancer	7.25e-07	7.59e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.17e-07	7.5e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.1e-07	7.43e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—hematologic cancer	7.1e-07	7.43e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—hematologic cancer	7.04e-07	7.37e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—hematologic cancer	7.03e-07	7.36e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—hematologic cancer	7.01e-07	7.34e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—hematologic cancer	7.01e-07	7.34e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3R1—hematologic cancer	7.01e-07	7.33e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—hematologic cancer	7.01e-07	7.33e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—hematologic cancer	7e-07	7.33e-06	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—hematologic cancer	6.97e-07	7.29e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CREBBP—hematologic cancer	6.95e-07	7.27e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—hematologic cancer	6.83e-07	7.15e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.78e-07	7.09e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—EP300—hematologic cancer	6.72e-07	7.03e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1A—hematologic cancer	6.69e-07	7e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—hematologic cancer	6.68e-07	6.99e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—hematologic cancer	6.63e-07	6.94e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—hematologic cancer	6.59e-07	6.89e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—hematologic cancer	6.53e-07	6.84e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—hematologic cancer	6.52e-07	6.82e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—hematologic cancer	6.5e-07	6.8e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—hematologic cancer	6.47e-07	6.77e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—hematologic cancer	6.47e-07	6.77e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOR1—hematologic cancer	6.44e-07	6.73e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—hematologic cancer	6.44e-07	6.73e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—hematologic cancer	6.43e-07	6.73e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—EP300—hematologic cancer	6.37e-07	6.66e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CREBBP—hematologic cancer	6.33e-07	6.63e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3R1—hematologic cancer	6.22e-07	6.51e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—hematologic cancer	6.19e-07	6.48e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—hematologic cancer	6.04e-07	6.32e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—hematologic cancer	6.01e-07	6.28e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—hematologic cancer	5.97e-07	6.25e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—hematologic cancer	5.96e-07	6.23e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—hematologic cancer	5.74e-07	6.01e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—hematologic cancer	5.7e-07	5.97e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—hematologic cancer	5.69e-07	5.95e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3R1—hematologic cancer	5.67e-07	5.93e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—hematologic cancer	5.59e-07	5.85e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—hematologic cancer	5.55e-07	5.8e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—hematologic cancer	5.55e-07	5.8e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—hematologic cancer	5.53e-07	5.79e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—hematologic cancer	5.37e-07	5.61e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—EP300—hematologic cancer	5.33e-07	5.58e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—hematologic cancer	5.23e-07	5.48e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—hematologic cancer	5.13e-07	5.37e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—hematologic cancer	5.13e-07	5.36e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.01e-07	5.24e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—hematologic cancer	4.97e-07	5.2e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—hematologic cancer	4.96e-07	5.19e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—hematologic cancer	4.91e-07	5.14e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—hematologic cancer	4.78e-07	5e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—EP300—hematologic cancer	4.73e-07	4.95e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—hematologic cancer	4.71e-07	4.93e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—hematologic cancer	4.53e-07	4.74e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—hematologic cancer	4.52e-07	4.73e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CREBBP—hematologic cancer	4.43e-07	4.64e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—hematologic cancer	4.36e-07	4.56e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—EP300—hematologic cancer	4.31e-07	4.51e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—hematologic cancer	4.2e-07	4.4e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—hematologic cancer	4.17e-07	4.36e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—hematologic cancer	4.15e-07	4.34e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—hematologic cancer	4.06e-07	4.25e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.97e-07	4.15e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—hematologic cancer	3.94e-07	4.13e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—hematologic cancer	3.85e-07	4.03e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—hematologic cancer	3.66e-07	3.83e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—hematologic cancer	3.5e-07	3.66e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—hematologic cancer	3.22e-07	3.37e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—hematologic cancer	3.19e-07	3.34e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—hematologic cancer	3.16e-07	3.31e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—EP300—hematologic cancer	3.02e-07	3.16e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—hematologic cancer	2.86e-07	2.99e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—hematologic cancer	2.61e-07	2.73e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—hematologic cancer	2.23e-07	2.34e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—hematologic cancer	1.82e-07	1.91e-06	CbGpPWpGaD
